Claims
- 1. A compound having any one of the following structures:
- 2. A method for temporally releasing NO from a compound having any one of the following structures:
- 3. The method of claim 2 wherein the wavelength sufficient to release NO from the compound is between 250-700 nm.
- 4. A method of administering nitric oxide to cells comprising administering to the cells an effective amount of a nitric oxide releasing prodrug including any one of the following structures:
- 5. The method of claim 4 wherein the NO releasing prodrug is administered to the cells topically.
- 6. The method of claim 4 wherein the NO releasing prodrug is administered to the cells by injection.
- 7. The method of claim 4 wherein the NO releasing prodrug is administered to the cells by being suspended into aqueous media.
- 8. The method of claim 4 wherein the cells are stored platelets.
- 9. A method for the pathogen inactivation of blood or a blood product comprising the steps of:
adding to the blood or blood product an effective amount of any one or more of the following structures: 1920wherein: X=—NR1R2, where R1 and R2 are selected from the group consisting of —H, —C1 through —C12 alkyl, phenyl, substituted phenyl, —R′NH2, and —R′—NH—R″, where R′ and R″ are alkyl groups including straight chain and branched groups, as well as cycloalkcyl, and where X may also equal prolinyl, imidizoyl, pyrrolyl, or pyridyl, where these groups are bonded at N; Y=—H, —C1 through —C12 alkyl, phenyl, substituted phenyl, —OR′, or —NR′R″, where R′ and R″ are alkyl groups including straight chain and branched groups, as well as cycloalkyl; R1-R7=—H, —C1 through —C12 alkyl, phenyl, substituted phenyl, —OH, —OR′, —O(CH2CH2O)nH, where n=1-12, —NH2, —NR′R″, —SH, —SR′, —R′CO2H, —R′CO2R″, —OR′CO2H, —OR′CO2R″, C(O)H, C(O)R1, or CH2OH, where R′ and R″ are alkyl groups including straight chain and branched groups, as well as cycloalkyl, and where R1-R7 may also equal any sugar or carbohydrate where this group is bonded at O; and exposing the mixture to light for a time sufficient to release nitric oxide from any one or more of the substituted diazeniumdiolate compounds, and inactivate any pathogens contained in the blood or blood product.
- 10. A method according to claim 9 further including the step of adding a photosensitizer to the blood or blood product to be pathogen inactivated.
- 11. A compound having any one of the following structures:
RELATED U.S. APPLICATION DATA
[0001] This application claims priority from U.S. Provisional Application 60/304413 filed on Jul. 12, 2001.
SUPPORT
[0002] The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Contract No. GM 58109-04 awarded by National Institutes of Health.
[0003] Support was also received from the American Cancer Society, and a Camille Dreyfus Teacher-Scholar Award, Camille and Henry Dreyfus Foundation.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US02/21925 |
7/12/2002 |
WO |
|